Dr. Arkenau Discusses the Future of Immunotherapy in Melanoma

September 24, 2015
Hendrik-Tobias Arkenau, MD, PhD

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the future of immunotherapy in melanoma.

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the future of immunotherapy in melanoma.

In the past, the initial successful data of CTLA-4 blockade with ipilimumab resulted in a response rate of about 10%. Today, there are combinations with ipilumumab and evolumab, with response rates in the range of 60%, so there have been very strong results.

Arkenau says it is exciting that the response rates are improving with these combinations and result in prolonged progression-free survival.